Bosutinib shine Src / Abl dual tyrosine kinase inhibitor wanda aka amince da shi don maganin sabon kamuwa da cuta na zamani (CP) cutar sankarar bargo ta myelogenous (CML), ko juriya ko rashin haƙuri ga CML jiyya na baya. Binciken ya kwatanta bayanai daga layin farko na besutinib da imatinib jiyya a ≥24 watanni na biyo baya. BFORE wani ci gaba ne, bude-lakabi na binciken asibiti na III tare da jimlar 536 marasa lafiya da aka yi rajista kuma an ba da izini don karɓar bursatinib (n = 268) ko imatinib (n = 268) a cikin 1: 1 rabo magani.
At a follow-up of 12 months, compared with the imatinib group, the bosutinib group showed higher molecular remission (MR) and complete cytogenetic remission (CCyR). Kuma wannan bambancin ya ci gaba da bin bayan watanni 24. A cikin watanni 24 na biye, ƙungiyoyi biyu sun nuna babban bambancin gafarar kwayoyin (MMR), amma bambancin dake tsakanin MR4 da MR4.5 bai da mahimmanci. Idan aka kwatanta da ƙungiyar imatinib, lokacin isa MR da CCyR ya fi guntu a cikin ƙungiyar bosutinib. Marasa lafiya shida a cikin ƙungiyar bosutinib da marasa lafiya bakwai a cikin ƙungiyar imatinib sun canza zuwa cikin hanzari / hanzari. A cikin watanni 24 na biyo baya, idan aka kwatanta da ƙungiyar imatinib, ƙungiyar bosutinib ta nuna babban haɓakar ƙwayoyin cuta (MMR). Karatu suna tallafawa yin amfani da bosutinib a cikin layin farko na marasa lafiya na CP CML.
